The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Haemonetics Corp's Score
Industry at a Glance
Industry Ranking
17 / 209
Overall Ranking
71 / 4611
Industry
Healthcare Equipment & Supplies
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
11
analysts
Buy
Current Rating
85.100
Target Price
+24.49%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Haemonetics Corp Highlights
StrengthsRisks
Haemonetics Corporation is a global healthcare company. The Company is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. The Company’s technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. The Company’s Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management products.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 16.44% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 1.36B.
Undervalued
The company’s latest PE is 20.53, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 54.60M shares, decreasing 8.66% quarter-over-quarter.
Haemonetics Corporation is a global healthcare company. The Company is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. The Company’s technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. The Company’s Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management products.